Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Total Valuation
Dermata Therapeutics has a market cap or net worth of $3.96M. The enterprise value is -$475.87K.
Market Cap$3.96M
Enterprise Value-$475.87K
Share Statistics
Dermata Therapeutics has 681,557 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding681,557
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dermata Therapeutics’s return on equity (ROE) is -7.87 and return on invested capital (ROIC) is -801.57%.
Return on Equity (ROE)-7.87
Return on Assets (ROA)-3.48
Return on Invested Capital (ROIC)-801.57%
Return on Capital Employed (ROCE)-8.02
Revenue Per Employee0.00
Profits Per Employee-1.54M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dermata Therapeutics is ―. Dermata Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.13
Price to FCF―
Price to Operating Cash Flow-0.56
PEG Ratio―
Income Statement
In the last 12 months, Dermata Therapeutics had revenue of 0.00 and earned -12.29M in profits. Earnings per share was -80.32.
Revenue0.00
Gross Profit0.00
Operating Income-12.51M
Pretax Income-12.29M
Net Income-12.29M
EBITDA-12.29M
Earnings Per Share (EPS)-80.32
Cash Flow
In the last 12 months, operating cash flow was -10.96M and capital expenditures -3.00, giving a free cash flow of -10.96M billion.
Operating Cash Flow-10.96M
Free Cash Flow-10.96M
Free Cash Flow per Share-16.08
Dividends & Yields
Dermata Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-72.19%
50-Day Moving Average6.74
200-Day Moving Average9.94
Relative Strength Index (RSI)41.47
Average Volume (3m)25.11K
Important Dates
Dermata Therapeutics upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Dermata Therapeutics as a current ratio of 1.79, with Debt / Equity ratio of 0.00%
Current Ratio1.79
Quick Ratio1.79
Debt to Market Cap0.00
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dermata Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dermata Therapeutics EV to EBITDA ratio is 0.24, with an EV/FCF ratio of 0.26.
EV to Sales0.00
EV to EBITDA0.24
EV to Free Cash Flow0.26
EV to Operating Cash Flow0.26
Balance Sheet
Dermata Therapeutics has $6.48M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$6.48M billion.
Cash & Marketable Securities$6.48M
Total Debt$0.00
Net Cash-$6.48M
Net Cash Per Share-$9.51
Tangible Book Value Per Share$10.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dermata Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside-49.83% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast75.79%